利妥昔单抗与血浆置换在伴严重肾病的ANCA相关血管炎中的疗效
该回顾性队列纳入467例活动性肾脏受累的AAV患者,其中251例为严重肾病(eGFR<30 ml/min per 1.73 m2)。利妥昔单抗(RTX)与环磷酰胺(CYC)在6个月诱导缓解上相当,加用血浆置换(PLEX)在缓解、ESKD/死亡、进展至ESKD及24个月生存上均未见获益。
要点
- 严重肾病AAV中RTX与CYC诱导缓解疗效相当。
- 加用PLEX未改善6个月缓解、18个月ESKD/死亡或24个月生存。
- 诊断时eGFR<15与不良结局独立相关,6个月肾脏缓解与肾脏恢复提示预后更好。
核心结论
- 在伴严重肾病的AAV患者中,CYC与RTX用于诱导治疗的获益与风险总体均衡,加用PLEX在本队列中未见获益。
- 作者认为评价该人群诱导治疗疗效仍需随机对照试验。
研究设计与样本
- 回顾性队列研究,纳入MPO-或PR3-ANCA阳性且eGFR<30 ml/min per 1.73 m2的AAV(MPA和GPA)患者。
- 467例活动性肾脏受累患者中251例为严重肾病;161例接受CYC、64例接受RTX诱导,51例同时接受PLEX。
主要发现
- 18个月ESKD和/或死亡的预测因素包括诊断时eGFR<15 ml/min per 1.73 m2(IRR 3.09 [95% CI 1.49 to 6.40],P=0.002)。
- 肾脏恢复(IRR 0.27 [95% CI 0.12 to 0.64],P=0.003)与6个月肾脏缓解(IRR 0.40 [95% CI 0.18 to 0.90],P=0.027)与较低的18个月ESKD和/或死亡相关。
- RTX与CYC在6个月诱导缓解(BVAS/WG=0)上相当(IRR 1.37 [95% CI 0.91 to 2.08],P=0.132)。
- 加用PLEX对6个月诱导缓解(IRR 0.73 [95% CI 0.44 to 1.22],P=0.230)、18个月ESKD和/或死亡(IRR 1.05 [95% CI 0.51 to 2.18],P=0.891)、进展至ESKD(IRR 1.06 [95% CI 0.50 to 2.25],P=0.887)及24个月生存(IRR 0.54 [95% CI 0.16 to 1.85],P=0.330)均无获益。
关键数值与推荐
- 严重肾病定义为eGFR<30 ml/min per 1.73 m2。
- 6个月诱导缓解以BVAS/WG=0判定。
- 主要比较指标包括缓解、复发、ESKD和死亡。
临床怎么用
- 伴严重肾病的AAV诱导治疗中,RTX与CYC均可作为选择,疗效在本队列中相当。
- 不应仅基于本回顾性数据常规加用PLEX,其获益需随机对照试验证实。
- 诊断时eGFR<15 ml/min per 1.73 m2提示预后较差,应加强监测与随访。
局限性
- 为回顾性队列研究,治疗分配可能存在选择偏倚。
- PLEX组样本量较小(51例),可能影响对疗效的检验效能。
- 作者指出需随机对照试验才能可靠评价诱导治疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of patients with ANCA-associated vasculitis (AAV) and severe renal involvement is not established. We describe outcomes in response to rituximab (RTX) versus cyclophosphamide (CYC) and plasma exchange (PLEX). METHODS: A retrospective cohort study of MPO- or PR3-ANCA-positive patients with AAV (MPA and GPA) and severe kidney disease (eGFR <30 ml/min per 1.73 m2). Remission, relapse, ESKD and death after remission-induction with CYC or RTX, with or without the use of PLEX, were compared. RESULTS: Of 467 patients with active renal involvement, 251 had severe kidney disease. Patients received CYC (n=161) or RTX (n=64) for remission-induction, and 51 were also treated with PLEX. Predictors for ESKD and/or death at 18 months were eGFR <15 ml/min per 1.73 m2 at diagnosis (IRR 3.09 [95% CI 1.49 to 6.40], P=0.002), renal recovery (IRR 0.27 [95% CI 0.12 to 0.64], P=0.003) and renal remission at 6 months (IRR 0.40 [95% CI 0.18 to 0.90], P=0.027). RTX was comparable to CYC in remission-induction (BVAS/WG=0) at 6 months (IRR 1.37 [95% CI 0.91 to 2.08], P=0.132). Addition of PLEX showed no benefit on remission-induction at 6 months (IRR 0.73 [95% CI 0.44 to 1.22], P=0.230), the rate of ESKD and/or death at 18 months (IRR 1.05 [95% CI 0.51 to 2.18], P=0.891), progression to ESKD (IRR 1.06 [95% CI 0.50 to 2.25], P=0.887), and survival at 24 months (IRR 0.54 [95% CI 0.16 to 1.85], P=0.330). CONCLUSIONS: The apparent benefits and risks of using CYC or RTX for the treatment of patients with AAV and severe kidney disease are balanced. The addition of PLEX to standard remission-induction therapy showed no benefit in our cohort. A randomized controlled trial is the only satisfactory means to evaluate efficacy of remission-induction treatments in AAV with severe renal involvement.
引用
- Casal Moura M, Irazabal MV, Eirin A, et al. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease. J Am Soc Nephrol. 2020. PMID: 32826324. doi:10.1681/ASN.2019111197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。